Nan Su, Lei Jiang, Yanpeng Wang, Yanping Dong, Yanjuan Yong, Kan Yang, Shixiong Gao
{"title":"I-III 型干扰素在斯约格伦综合征和非斯约格伦干眼症中的表达。","authors":"Nan Su, Lei Jiang, Yanpeng Wang, Yanping Dong, Yanjuan Yong, Kan Yang, Shixiong Gao","doi":"10.1159/000540295","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Systemic implications create a critical need for identification of dry eye patients with Sjögren syndrome (SS). Herein, we aimed to determine expressions of type I-III interferons (IFNs) in dry eye patients with or without underlying SS and their differential diagnosis.</p><p><strong>Methods: </strong>A prospective, observational, case-control study was performed on 140 dry eye patients among which 78 patients were diagnosed with SS. Clinical evaluations included ELISA detections of serum type I IFN (IFN-α and IFN-β, type II IFN (IFN-γ), and type III IFN (IFN-λ1/IL-29, IFN-λ2/IL-28, and IFN-λ3/IL-28B), as well as reporter cell assay for serum type I IFN activity.</p><p><strong>Results: </strong>The serum levels of IFN-α and IFN-β were notably higher in dry eye patients with SS than those without underlying SS (p < 0.0001). The functional assay for serum type I IFN activity showed the mean summed scores in dry eye patients with SS were remarkably increased compared to those without underlying SS (p < 0.0001). The serum levels of IFN-γ and IFN-λ1/IL-29 seemed higher in dry eye patients with SS than those without underlying SS (p < 0.0001). The serum levels of type I IFN (IFN-α combined with IFN-β), type II IFN (IFN-γ level), and type III IFN (IFN-λ1/IL-29) used as a test to predict underlying SS among dry eye patients produced an area under the curve of 0.86, 0.73, and 0.94, respectively.</p><p><strong>Conclusion: </strong>Serum levels of type I-III IFNs, especially IFN-α, IFN-β, and IFN-λ1/IL-29, may serve as a useful biomarker for identification of SS dry eye from non-SS dry eye.</p>","PeriodicalId":19662,"journal":{"name":"Ophthalmic Research","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Expressions of Type I-III Interferons in Sjögren's Syndrome and Non-Sjögren's Dry Eye.\",\"authors\":\"Nan Su, Lei Jiang, Yanpeng Wang, Yanping Dong, Yanjuan Yong, Kan Yang, Shixiong Gao\",\"doi\":\"10.1159/000540295\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Systemic implications create a critical need for identification of dry eye patients with Sjögren syndrome (SS). Herein, we aimed to determine expressions of type I-III interferons (IFNs) in dry eye patients with or without underlying SS and their differential diagnosis.</p><p><strong>Methods: </strong>A prospective, observational, case-control study was performed on 140 dry eye patients among which 78 patients were diagnosed with SS. Clinical evaluations included ELISA detections of serum type I IFN (IFN-α and IFN-β, type II IFN (IFN-γ), and type III IFN (IFN-λ1/IL-29, IFN-λ2/IL-28, and IFN-λ3/IL-28B), as well as reporter cell assay for serum type I IFN activity.</p><p><strong>Results: </strong>The serum levels of IFN-α and IFN-β were notably higher in dry eye patients with SS than those without underlying SS (p < 0.0001). The functional assay for serum type I IFN activity showed the mean summed scores in dry eye patients with SS were remarkably increased compared to those without underlying SS (p < 0.0001). The serum levels of IFN-γ and IFN-λ1/IL-29 seemed higher in dry eye patients with SS than those without underlying SS (p < 0.0001). The serum levels of type I IFN (IFN-α combined with IFN-β), type II IFN (IFN-γ level), and type III IFN (IFN-λ1/IL-29) used as a test to predict underlying SS among dry eye patients produced an area under the curve of 0.86, 0.73, and 0.94, respectively.</p><p><strong>Conclusion: </strong>Serum levels of type I-III IFNs, especially IFN-α, IFN-β, and IFN-λ1/IL-29, may serve as a useful biomarker for identification of SS dry eye from non-SS dry eye.</p>\",\"PeriodicalId\":19662,\"journal\":{\"name\":\"Ophthalmic Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmic Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000540295\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000540295","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
导言：干眼症（SS）对全身的影响导致了识别干眼症患者的迫切需要。在此，我们旨在确定 I-III 型干扰素（IFNs）在有或没有潜在斯约格伦综合征的干眼症患者中的表达及其鉴别诊断：方法：我们对 140 名干眼症患者进行了一项前瞻性、观察性、病例对照研究，其中 78 名患者被诊断为 SS。临床评估包括血清 I 型 IFN（IFN-α 和 IFN-β）、II 型 IFN（IFN-γ）和 III 型 IFN（IFN-λ1/IL-29、IFN-λ2/IL-28 和 IFN-λ3/IL-28B）的 ELISA 检测，以及血清 I 型 IFN 活性的报告细胞检测：结果：患有 SS 的干眼症患者血清中 IFN-α 和 IFN-β 的水平明显高于无基础 SS 的患者（p < 0.0001）。对血清 I 型 IFN 活性的功能测试显示，与没有潜在 SS 的干眼症患者相比，患有 SS 的干眼症患者的平均总分显著增加（p < 0.0001）。患有 SS 的干眼症患者血清中 IFN-γ 和 IFN-λ1/IL-29 的水平似乎高于没有潜在 SS 的患者（p < 0.0001）。用于预测干眼症患者潜在 SS 的 I 型 IFN（IFN-α 与 IFN-β）、II 型 IFN（IFN-γ 水平）和 III 型 IFN（IFN-λ1/IL-29）血清水平的 AUC 分别为 0.86、0.73 和 0.94：结论：血清中 I-III 型 IFNs（尤其是 IFN-α、IFN-β 和 IFN-λ1/IL-29）的水平可作为鉴别 SS 干眼和非 SS 干眼的有用生物标志物。
Expressions of Type I-III Interferons in Sjögren's Syndrome and Non-Sjögren's Dry Eye.
Introduction: Systemic implications create a critical need for identification of dry eye patients with Sjögren syndrome (SS). Herein, we aimed to determine expressions of type I-III interferons (IFNs) in dry eye patients with or without underlying SS and their differential diagnosis.
Methods: A prospective, observational, case-control study was performed on 140 dry eye patients among which 78 patients were diagnosed with SS. Clinical evaluations included ELISA detections of serum type I IFN (IFN-α and IFN-β, type II IFN (IFN-γ), and type III IFN (IFN-λ1/IL-29, IFN-λ2/IL-28, and IFN-λ3/IL-28B), as well as reporter cell assay for serum type I IFN activity.
Results: The serum levels of IFN-α and IFN-β were notably higher in dry eye patients with SS than those without underlying SS (p < 0.0001). The functional assay for serum type I IFN activity showed the mean summed scores in dry eye patients with SS were remarkably increased compared to those without underlying SS (p < 0.0001). The serum levels of IFN-γ and IFN-λ1/IL-29 seemed higher in dry eye patients with SS than those without underlying SS (p < 0.0001). The serum levels of type I IFN (IFN-α combined with IFN-β), type II IFN (IFN-γ level), and type III IFN (IFN-λ1/IL-29) used as a test to predict underlying SS among dry eye patients produced an area under the curve of 0.86, 0.73, and 0.94, respectively.
Conclusion: Serum levels of type I-III IFNs, especially IFN-α, IFN-β, and IFN-λ1/IL-29, may serve as a useful biomarker for identification of SS dry eye from non-SS dry eye.
期刊介绍：
''Ophthalmic Research'' features original papers and reviews reporting on translational and clinical studies. Authors from throughout the world cover research topics on every field in connection with physical, physiologic, pharmacological, biochemical and molecular biological aspects of ophthalmology. This journal also aims to provide a record of international clinical research for both researchers and clinicians in ophthalmology. Finally, the transfer of information from fundamental research to clinical research and clinical practice is particularly welcome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
